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ABSTRACT
Pulmonary hypertension is relatively common in children
and has many causes. The management of the condition
has changed dramatically in the past 5 years with the
introduction of new medicines. However, diagnosis,
investigation and choice of therapy remain a challenge. In
2002 the United Kingdom Pulmonary Hypertension
Service for Children was established and this has become
the mainstay of management in this country. This service,
based at Great Ormond Street Hospital for Children,
provides advice, expertise and infrastructure support for
the most severely affected patients, particularly those
with idiopathic pulmonary arterial hypertension for whom
chronic intravenous prostacyclin remains the most
effective medication. New medicines are being developed
which, rather than focussing on dilating a diseased
pulmonary vascular bed, aim to structurally remodel the
pulmonary vasculature towards normal.
Pulmonary hypertension is more common in
children than in adults. A modest elevation in
pulmonary arterial pressure (PAP) is tolerable, but
a high pressure is associated with obstructive
pulmonary vascular disease leading to right heart
failure and death. Our perspective on this condi-
tion has changed dramatically since I wrote an
editorial for this journal in 1998.
1 Improved
diagnostic techniques facilitate assessment, drug
discoveries have revolutionised management and
the establishment of a UK Service for the Care of
Children with Pulmonary Hypertension has facili-
tated diagnosis and management and provided
infrastructure support to improve the quality of
life of the most severely affected children. We now
have a clinically useful classification of pulmonary
hypertension which includes all the types of
pulmonary hypertension encountered in childhood
(box 1).
2 We have also established internationally
recognised diagnostic and management guide-
lines.
34 This review is based on the experience
gained in establishing and running the UK Service
for Children, a service commissioned by the
Specialist Commissioning Group. The service is a
structured clinical network designed to treat
children with pulmonary hypertension rapidly
and to provide immediate access to new medicines.
Pulmonary hypertension is defined as a mean
PAP equal to or greater than 25 mm Hg at rest or
30 mm Hg on exercise, a definition which applies
to all but the youngest infants. The aetiology is
more diverse in paediatric than adult patients (box
1). Pulmonary arterial hypertension is much more
common than venous hypertension, particularly in
childhood, and the new therapies target arterial
rather than venous disease. Pulmonary arterial
hypertension is subdivided into idiopathic pulmon-
ary arterial hypertension (IPAH), formerly known
as primary pulmonary hypertension, and asso-
ciated pulmonary arterial hypertension (APAH)
when associated with other disorders such as
congenital heart disease, connective tissue or lung
disease.
2 There is as yet no evidence of ethnic
variability in the different types of pulmonary
hypertension seen in British children.
In 1998 the only drugs available to treat
pulmonary hypertension were calcium channel
antagonists and intravenous epoprostenol,
although epoprostenol was only shown to be
efficacious in children with IPAH in 1999.
5 Now
there are effective endothelial receptor antagonists,
phosphodiesterase inhibitors and prostacyclin ana-
logues, the first two groups of drugs being effective
orally.
DIAGNOSTIC STRATEGY
Clinical suspicion of pulmonary hypertension (fig 1)
Pulmonary hypertension should be suspected in
any child who is unduly short of breath, tires easily
or is syncopal when there is no evidence of heart or
lung disease. Children occasionally complain of
chest pain. The disorder should also be suspected in
those known to suffer from these diseases when
increasing shortness of breath cannot be explained
by the underlying disease process itself. The
physical signs of pulmonary hypertension include
a left parasternal, right ventricular lift, an accen-
tuated pulmonary component of the second heart
sound and sometimes cool extremities. A diastolic
murmur of pulmonary regurgitation may be
present, but signs of overt right heart failure are a
late event in young children.
Confirming the clinical suspicion of pulmonary
hypertension
An accurate and complete diagnosis is essential,
remembering that dual pathology is not uncom-
mon in children with pulmonary hypertension. A
chest x ray, ECG and a transthoracic Doppler
echocardiogram are mandatory (fig 1). The classical
findings include a chest x ray showing enlarged
central pulmonary arteries and diminished periph-
eral pulmonary vascular markings. ECG findings
include evidence of right ventricular dilatation and
hypertrophy which can be confirmed by transthor-
acic echocardiography. Doppler interrogation can
estimate pulmonary arterial systolic and diastolic
pressures. The right ventricular systolic pressure
(RVSP) is estimated from the systolic regurgitant
tricuspid flow velocity v and the estimated right
atrial pressure (RAP) in the Bernouille equation:
RVSP=4v
2+RAP. A tricuspid regurgitant jet is
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620 Arch Dis Child 2008;93:620–625. doi:10.1136/adc.2007.120493present in the majority of pulmonary hypertensive patients.
Echocardiographic measures of right ventricular function
include the Tei index which is the sum of the isovolumetric
contraction time and isovolumetric relaxation time divided by
the ejection time. It assesses both systolic and diastolic
function. The tricuspid annular plane systolic excursion
(TAPSE) correlates with the right ventricular ejection fraction.
Blood tests may show hyperuricaemia, particularly in
Eisenmenger syndrome and elevation of brain natriuretic
peptide, although less reliably than in adults.
6
Functional capacity is graded according to the NYHA/WHO
classification, from the asymptomatic patient in class I to the
severely disabled in class IV. Shortness of breath is a common
complaint and an objective assessment of exercise capacity is
helpful. In a co-operative child aged 6 years or more the results
of a 6 min walk test can be compared with those in normal
children of the same age and sex.
7 Cardiopulmonary exercise
testing to determine maximum VO2, work rate and anaerobic
threshold can also be helpful, but this test should be carried out
after the severity of the pulmonary hypertension has been
ascertained at cardiac catheterisation, and stressing the child in
this way is thought to be safe.
Classification of pulmonary hypertension: determining causation
If the chest x ray excludes parenchymal lung disease, and
echocardiography excludes an intracardiac anomaly, then the
child probably has IPAH (fig 1). Rarely, pulmonary veno-
occlusive disease (PVOD) can masquerade as IPAH. Evaluation
must exclude a potentially remedial cause of pulmonary
hypertension. The age of the child will obviously determine
the ease and success with which certain investigations, such as
lung function tests, can be carried out.
Any child suspected of having IPAH or PVOD/pulmonary
capillary haemangiomatosis (PCH) should be referred imme-
diately to the UK Pulmonary Hypertension Service for
Children.
IPAH
Presentation
Patients can present throughout childhood, even in infancy.
Symptoms vary, are age related and often non-specific. Syncope
is relatively common. The commonest misdiagnosis is asthma.
Parents report shortness of breath without wheeze, unrespon-
sive to bronchodilator therapy. The familial form of IPAH,
which accounts for 6% of all cases, shows genetic anticipation,
presentation occurring at a younger age in successive genera-
tions.
89Mutations in the bone morphogenetic receptor-II gene
account for the majority of cases of familial IPAH and 26% of
sporadic cases.
10 Pulmonary hypertension also occurs in families
with hereditary haemorrhagic telangectasia (HHT) caused by
mutations in the activin-like kinase 1 (ALK-1) and endoglin
genes.
11 Taking a careful family history and examining
specifically for evidence of HHT is important.
Investigation
The systemic arterial oxygen saturation is normal in the
absence of an atrial septal defect. Desaturation can occur in
the presence of an atrial communication when the PAP, right
ventricular and atrial pressures increase and right to left
shunting occurs. The ECG findings are characteristic, and
include right axis deviation, evidence of right ventricular
hypertrophy with or without a strain pattern and right atrial
enlargement. In addition to an abnormal chest x ray, contrast
enhanced spiral CT of the lungs is indicated in older patients
to exclude thrombus in the central pulmonary arteries and
chronic thrombo-embolic disease. It is also helpful in
distinguishing IPAH from PVOD. Ventilation/perfusion scans
can be normal in IPAH but may show small peripheral non-
segmental perfusion defects. Magnetic resonance imaging can
help assess right ventricular function but is not yet part of the
routine investigation in children with IPAH. The echocardio-
gram generally reveals dilated right heart chambers, right
ventricular hypertrophy with posterior bowing of the ven-
tricular and, in the absence of an atrial communication, the
atrial septum.
12 The left ventricle may be severely compressed.
Right atrial size and left ventricular eccentricity index are
predictive of outcome in adults and are routinely assessed in
children. Lung function testing can sometimes demonstrate
small airways obstruction.
In addition to routine haematology and biochemistry, thyroid
function tests, a thrombophilia screen including antiphospho-
lipid antibodies (lupus anticoagulant, anticardiolpin antibodies)
and an auto-immune screen are carried out. Children may
seroconvert when they are older. Some children have an
immunoglobulin deficiency. They may have a low level of
antithrombin III, protein S or protein C, which may be genetic
in origin or result from a consumption coagulopathy.
Screening of other siblings for the familial form of the disease
is necessary.
Box 1 Classification of pulmonary hypertension
1. Pulmonary arterial hypertension (PAH)
c 1.1 Idiopathic (IPAH)
c 1.2 Familial (FIPAH)
c 1.3 Associated with (APAH)
– 1.3.1 Connective tissue disease
– 1.3.2 Congenital systemic to pulmonary shunts
– 1.3.3 Portal hypertension
– 1.3.4 HIV
– 1.3.5 Drugs and toxins
– 1.3.6 Other
c 1.4 Associated with significant venous or capillary
involvement
– 1.4.1 Pulmonary veno-occlusive disease
– 1.4.2 Pulmonary capillary haemangiomatosis
c 1.5 Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension associated with left heart diseases
c 2.1 Left sided atrial or ventricular disease
c 2.2 Left sided valvular heart disease
3. Pulmonary hypertension associated with respiratory disease
and/or hypoxia
c 3.1 Chronic obstructive pulmonary disease
c 3.2 Interstitial lung disease
c 3.3 Sleep disordered breathing
c 3.4 Alveolar hypoventilation disorders
c 3.5 High altitude
c 3.6 Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic/embolic
disease
5. Miscellaneous
c Tumour, and others
Indicated in italics are the only conditions NOT to have been
encountered in the UK Pulmonary Hypertension Service for
Children.
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Successful treatment of the pulmonary hypertension depends
on the rapidity with which the physician treating the under-
lying disease recognises that pulmonary hypertension is a major
complicating factor in the clinical picture.
Presentation and the investigation of children with APAH are
determined by the underlying disease process. The principle
aetiologies are as follows.
Chronic hypoxia
Chronic hypoxia leads to pulmonary hypertension. Chronic
lung disease of prematurity is a relatively common cause of
moderate pulmonary hypertension. Interstitial lung disease, as
strictly defined, is uncommon in children, as are the pulmonary
complications of connective tissue disease. When pulmonary
hypertension does occur in association with connective tissue
disease in children, it is usually severe. Of the developmental
abnormalities, the commonest association is congenital dia-
phragmatic hernia. In these patients pulmonary hypertension is
relatively common in the neonatal period. It usually abates but
can persist indefinitely, be severe and require long term
treatment. The extent to which lung disease is causing or
contributing to an elevated PAP is revealed by pulmonary
function tests, the blood gases, ventilation/perfusion and high
resolution CT scans.
Persistent pulmonary hypertension of the newborn (PPHN)
This condition is usually self-limiting unless there is a
significant irreversible underlying problem such as chronic
lung disease of prematurity. Alveolar hypoplasia, usually
accompanied by a degree of dysplasia, is signalled by persistent
failure to wean off the ventilator and an open lung biopsy may
be needed to guide management. PPHN may also be the first
indication of IPAH.
Congenital heart disease
Sustained pulmonary hypertension is sometimes recognised
following a technically successful intra-cardiac repair and can be
severe. Typically, the child improves clinically after the repair
but then becomes short of breath and tires easily. The more
severely affected children are investigated and treated as though
they had IPAH. Classical Eisenmenger syndrome in the patient
who initially had a large left to right shunt and then slowly
developed pulmonary vascular disease with shunt reversal,
central cyanosis and clubbing is not usually a problem in
childhood. Most patients begin to deteriorate in their teenage
years. Any child who appears to have Eisenmenger syndrome
should be evaluated carefully to ensure that the cardiac
diagnosis is correct and complete and that remedial surgery is
not feasible. Sleep studies may be indicated in those with
trisomy 21. Paediatric cardiology units are familiar with the
small group of children who had a high pulmonary vascular
resistance when first seen and were therefore deemed inoper-
able. In such children the resistance probably remained high
from birth. They frequently become symptomatic in childhood
and may benefit from medical therapy. Complex surgically
naive and post-operative cases for whom curative or palliative
surgery is not feasible frequently need reappraisal including
cardiac catheterisation with a view to palliation by medical
therapy.
Figure 1 Investigating pulmonary hypertension: diagnostic strategy. CXR, chest x ray; PH, pulmonary hypertension; V/Q, ventilation/perfusion.
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Pulmonary hypertension is a recognised complication of chronic
liver disease. Portal hypertension rather than hepatocellular
disease appears to be the main determinant. It is uncommon in
childhood but when present can influence the timing of liver
transplantation. In adults liver transplantation is contra-
indicated if the mean PAP exceeds 35 mm Hg and the
pulmonary vascular resistance is greater than 250 dynes/s/cm.
13
PVOD and PCH
These conditions are uncommon. They can present like IPAH,
but recognition is important because their management differs
from that of IPAH. PVOD usually presents with shortness of
breath, sometimes accompanied by small, frequent haemopty-
sis. The patient may be desaturated, clubbed and have minimal
rales on auscultation. The ECG and echocardiogram can be
indistinguishable from IPAH but the lung diffusing capacity is
lower and high resolution CT scans can be diagnostic to the
experienced radiologist. In addition to the expected features of
pulmonary hypertension, contrast CT with vascular imaging
shows a patchy centrilobular pattern of ground glass opacities,
the lobules having a ‘‘pavement appearance’’ because their
margins are demarcated by thickened septal lines caused by
oedema. Typically, mediastinal lymphadenopathy is prominent.
The contrast scan also confirms the echocardiographic findings
of unobstructed venous return in the large pulmonary veins.
These children are usually very ill indeed and should be listed for
transplantation without delay. Cardiac catheterisation may be
indicated to confirm the diagnosis. If the child is relatively well
and stable, it can be helpful to do an open lung biopsy in order
to distinguish those with PCH who may be amenable to
treatment for a short period of time, although such treatment
with anti-cancer drugs must be regarded as experimental.
Medical treatment of PVOD with pulmonary hypertension
specific therapies can be hazardous and is contraindicated.
Cardiac catheterisation to confirm the diagnosis, assess disease
severity and guide therapeutic management and the role of lung
biopsy
The purpose of cardiac catheterisation in children with
pulmonary hypertension is to confirm the diagnosis and to
ensure that the conclusions drawn from the non-invasive tests
were complete and accurate. The catheter also determines
disease severity by determining the PAP accurately, is the only
reliable means to date of determining pulmonary vascular
resistance and tests the vasoreactivity of the pulmonary
vasculature. The main determinant of treatment is the response
to vasodilator testing with nitric oxide at cardiac catheterisa-
tion. Pulmonary vascular resistance can only be determined
using the Fick principle if the pulmonary blood flow can be
determined accurately by measuring, rather than assuming, the
oxygen consumption.
The risk of both cardiac catheterisation and general anaes-
thesia are increased in the presence of pulmonary hypertension
and therefore the procedure is carefully planned after discussion
with the child’s parents. Adequate sedation, optimal ventilation
and meticulous attention to acid base status and blood loss is
mandatory. The clinical history and the haemodynamic findings
may indicate the need for further interventions such as the
creation of an atrial septostomy and/or insertion of a Hickman
line for continuous infusion of epoprostenol. These procedures
are best done under the one anaesthetic, but the family need to
be fully informed of their likelihood and significance and
consent to these procedures, or not, before the catheterisation
study can take place.
Lung biopsy is rarely justified in pulmonary hypertension.
The exceptions are suspicion of PVOD or PCH, of alveolar
hypoplasia/dysplasia in PPHN, and very rarely in children with
complex congenital heart disease in whom it might still be
possible to operate.
Treatment of pulmonary arterial hypertension
Immunisation schedules should be maintained, and young
children need respiratory syncytial virus prophylaxis with
palivizumab. Anaesthesia for any general surgical or dental
procedure requires particular care.
The aim of medical treatment is to dilate the pulmonary
vasculature and reverse the abnormal remodelling characteristic
of pulmonary vascular disease. The practical difficulties
encountered in treating children influence management and
include their age, level of understanding, size and in some, the
presence of other anomalies. Three signalling pathways are
targeted: the prostacyclin, endothelin and nitric oxide path-
ways.
Prostacyclin and its analogues
The most effective therapy is a continuous intravenous infusion
of epoprostenol, the sodium salt of prostacyclin. It has a short
half-life of 3–5 min, is unstable and the infusion has to be
prepared every 24 h. The principle side effects are jaw pain and
diarrhoea. The child is dosed according to response. Children
need much higher doses than adults. A more stable analogue of
prostacyclin, treprostinil, can also be given intravenously but is
associated with more prominent side effects, headaches and leg
pain. Meticulous care of the Hickman line is essential to prevent
local and systemic infections, the latter being extremely
uncommon. Treprostinil can also be given by continuous
subcutaneous infusion but is painful, the drug stimulating
nerve endings and causing induration and sometimes ulceration
of the skin.
14 It is not used in children. Iloprost is a prostacyclin
analogue which can be given by inhalation but small, tired
children find it difficult to inhale an effective dose every 2 h.
The drug is effective for less than 2 h.
Endothelin receptor antagonists
The dual endothelin (ET) receptor antagonist bosentan
(Tracleer) was the first oral drug shown to be efficacious in
IPAH and has been used extensively in this and other types of
pulmonary hypertension since its introduction in 2002.
15 It is
efficacious in children.
16 Its principle side effect is elevation of
liver enzymes which necessitates a monthly blood test. Drug
interactions can occur. Bosentan decreases effective exposure to
warfarin because of induction of CYP3A4 and/or CYP2C9. The
newer selective ET-A receptor antagonists, sitaxentan and
ambrisentan have not yet been studied in children. Both drugs
affect the liver less than bosentan and drug interaction is
probably less likely with ambrisentan.
Phosphodiesterase inhibitors
Sildenafil was the first drug of this class and is still the most
commonly used, particularly in young children with APAH. The
principle side effects include erections and systemic hypotension
when high doses are used. The dose is 0.5–1 mg/kg/dose, given
three to four times a day, rarely more.
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Patients with pulmonary vascular disease are prone to develop
thrombosis in situ. Older children are given warfarin and
younger ones usually receive aspirin. The INR must be
monitored particularly closely in those on endothelin receptor
antagonists.
Oxygen
Oxygen is a potent pulmonary vasodilator. Nocturnal supple-
mental oxygen is indicated if there is nocturnal systemic arterial
oxygen desaturation and can benefit those with a high PAP.
Atrial septostomy
This procedure is indicated in children with IPAH and post-
operative pulmonary hypertension suffering from syncope and/
or severe right heart failure.
17 It reduces the effect of a sudden
increase in pulmonary arterial and right heart pressures and
maintains a left ventricular output.
Lung and heart–lung transplantation
The policy of the UK Pulmonary Hypertension Service is to refer
children on intravenous epoprostenol for assessment by the
transplantation service when they are established on treatment
and are still well. They are then reviewed by the transplantation
service as indicated.
WHICH CHILDREN WILL BENEFIT FROM WHICH DRUG?
It is impossible to generalise about who should and should not
be treated. All children with IPAH need urgent treatment, but
in those with APAH it is the severity of the pulmonary
hypertension and the extent to which even a modest increase in
pressure influences their well-being and prognosis which
determines the need to treat.
Treating IPAH
Without treatment the expected survival is less than 1 year.
5
The main determinant of treatment is the response to
vasodilator testing with nitric oxide at cardiac catheterisation.
In those with a positive response the PAP and PVR (pulmonary
vascular resistance) must fall to a near normal level with no fall
in cardiac output. Only patients with a positive vasodilator
response can be treated with a calcium channel antagonist. This
applies to less than 10% of those with IPAH. Children who
improve and are stable on a calcium channel antagonist need
repeat cardiac catheterisation after 1 year or less, because they
can become resistant to the drug at any time and need
escalation of therapy before they deteriorate. The majority of
negative responders present in NYHA/WHO class III–IV and
frequently need to be started on intravenous epoprostenol
therapy immediately. In a minority it is feasible to initiate
therapy with an endothelial receptor antagonist. Most children
however, require dual therapy. Sildenafil has not been proven to
be efficacious in children. Syncopal children need an urgent
atrial septostomy. After discharge from hospital close monitor-
ing, principally by echocardiography, is mandatory since urgent
intensification of therapy is frequently necessary.
Treating APAH
Congenital heart disease
Children with severe post-operative pulmonary hypertension
are treated like those with IPAH. Symptomatic children with
classical Eisenmenger syndrome are treated either with an
endothelin receptor antagonist or sildenafil, according to age,
sex and maturation. Children with a high PVR who have never
been operable are usually more symptomatic at an early age and
need similar treatment.
Chronic lung and connective tissue disease
These patients are treated with bosentan which is thought to
have an anti-fibrotic effect in addition to treating pulmonary
vascular disease. Young and less severely affected children
receive sildenafil. Those with connective tissue disease may
require intravenous epoprostenol.
PPHN persisting beyond the neonatal period
Children with a modest increase in PAP are treated with
sildenafil unless it is apparent that resolution is not occurring
when therapy is intensified.
In both chronic lung disease and PPHN the aim is to
encourage normalisation of the pulmonary vasculature and so
be able to stop treatment with relatively new, powerful drugs
whose long term effects on children are unknown.
Bone marrow transplantation
Pulmonary hypertension can occur as a result of the condition
indicating bone marrow transplantation, be a complication of
transplantation or be an incidental finding. In any event,
treatment with bosentan is contraindicated because it interacts
with cyclosporine and tacrolimus. Sildenafil can be given to the
less severely affected, but intravenous epoprostenol may be
indicated.
Quality of life
All children are encouraged to return to school quickly. For
those on intravenous therapy, dedicated school carers are given
appropriate training by the clinical nurse specialists of the UK
Pulmonary Hypertension Service who visit the school regularly.
All drugs and equipment for intravenous, inhalational and oral
therapy are delivered directly to the child’s home. Psychological
support may be necessary, particularly with respect to mana-
ging relationships in a family with a chronically sick child. The
patients’ organisation, The Pulmonary Hypertension
Association UK, is a great source of comfort and support.
Hospice care also helps many families. It is the responsibility of
the UK Pulmonary Hypertension Service for Children to
establish support networks in the community for these families.
Improving quality of life must be the first priority when
treating an incurable disease. In the Quality of Life question-
naires completed by the parents and older children cared for by
the UK Pulmonary Hypertension Service the scores for physical
performance were low, as expected.
18 The psychosocial scores
were significantly higher, almost normal, a result which
probably indicates the extent to which expectations change in
chronic disease.
Lung transplantation
Patients who fail to respond to medical therapy are offered the
possibility of lung transplantation. The predicted survival for
lung transplantation in children is 4.3 years with a 75% survival
at 1 year.
19
Results of treatment
In IPAH, the UK Pulmonary Hypertension Service showed
survival figures of 84% at 1 year and 76% at 3 years.
18 In APAH
the survival rates were 89% at 1 year and 79% at 3 years. These
Review
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and paediatric studies.
New and emerging therapies
The therapeutic goal is the remodelling of the pulmonary
vasculature back to normal, the restoration of endothelial
function and the growth of new peripheral pulmonary arteries.
New modes of administration, new formulations and new
analogues of existing drugs, new endothelin receptor antago-
nists and new PDE 1/5/6 plus PDE-3 and PDE-1 inhibitors are in
development now. Statins, RhoA inhibitors, anti-growth factor
drugs, metalloproteinase inhibitors, K channel openers, stem cell
and gene therapy and vasoactive intestinal peptide are all under
investigation. At present we can stabilise patients for many
years, but new, radical medicines used in combination offer the
hope of cure and greater promise of tailoring the treatment to
the individual child.
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4th Fred J Epstein International Symposium on New Horizons in Pediatric Neurology,
Neurosurgery and Neurofibromatosis
15–19 March 2009, Eilat, Israel
A symposium for paediatric neurologists, neurosurgeons neuroradiologists, neuropathologists, neuro-
oncologists, neurogeneticists, neuroscientists, perinatologists and paediatricians
The symposium will provide an update in the diagnoses and management of diseases of the nervous
system in infants and children that may be treated surgically. An emphasis will be placed on joint,
rather than parallel sessions, with both neurological and neurosurgical approaches.
The faculty is comprised of recognised leaders in their respective fields. Special attention will be given
to controversial issues of common interest in patient management, new surgical-neuroradiological
techniques and oncological options.
The conference will be conducted in English.
Conference organisers are: Shlomi Constantini, Israel; Shaul Harel, Israel; Rick Abbott, USA; Susan
Bressman, USA; Kathy Epstein, USA; Roger J Packer, USA; Shlomo Shinnar, USA.
For more information please contact the Secretariat: Target Conferences Ltd,
PO Box 29041, Tel Aviv 61290, Israel: Tel: +972 3 5175150; Fax: +972 3 5175155; Email:
newhorizons@targetconf.com; Website: www.fredhorizons.com.
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